<DOC>
	<DOC>NCT00834106</DOC>
	<brief_summary>A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among Chinese females between the ages of 20 and 45.</brief_summary>
	<brief_title>Prevention of HPV in 20 to 45 Year Old Chinese Women (V501-041)</brief_title>
	<detailed_description>The Base Study V501-041 had a planned duration of 30 months. The study was extended to further evaluate the efficacy of Quadrivalent HPV (Type 6, 11, 16, 18) L1 VLP (qHPV) vaccine against Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), CIN 3, Adenocarcinoma In Situ (AIS), and/or cervical cancer. The total duration of the study extension is expected to be approximately 48 months, until the requisite number of primary efficacy endpoint cases (HPV 16/18-related CIN 2 or worse) has accrued over the total study period (base study and extension).</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy women between the ages of 20 and 45 Have used effective contraception for 2 weeks prior to starting in the study Does not have a temperature within 24 hours before the first injection Prior history of genital warts More than 4 lifetime sexual partners Have undergone hysterectomy Have active cervical disease or history of cervical disease</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HPV 6/11/16/18 Infection</keyword>
</DOC>